Technology ID
TAB-2349

New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins

E-Numbers
E-234-2011-0
E-234-2011-1
E-234-2011-2
Lead Inventor
Kovac, Pavol (NIDDK)
Co-Inventors
Xu, Peng (NIDDK)
Alam, Mohammed (Massachusetts General Hospital)
Kalsy, Anuj (Massachusetts General Hospital)
Charles, Richelle (Massachusetts General Hospital)
Calderwood, Stephen (Massachusetts General Hospital)
Peterson, Dwight (FDA)
Ryan, Edward (Massachusetts General Hospital (MGH))
Qadri, Firdausi (International Centre for Diarrhoeal Disease Research)
Vann, Willie (FDA)
Applications
Vaccines­­­
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
Early-stage
Lead IC
NIDDK
ICs
NIDDK
FDA
A new conjugate vaccine for cholera has been developed. The invention includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species (e.g. polysaccharides) directly to amine-containing species (e.g. proteins) without prior modification of either component. While demonstrated in this new cholera prototype vaccine, the technology is envisioned as generally applicable, thereby streamlining a complex production process.
Commercial Applications
  • Simplified production of conjugate vaccines
  • New vaccines
Competitive Advantages
  • The method in the present form is simple to perform, gives reproducible results, allows preparation of carbohydrate-protein constructs in a predictable way, and appears to be superior to protocols developed earlier.

Request More Info

Licensing Contact:
Buller, Carolyn
carolyn.buller@nih.gov

Patents

  • US
    Provisional (PRV) 61/507,054
    Filed on 2011-07-11
  • US
    Provisional (PRV) 61/569,632
    Filed on 2011-12-12
  • Patent Cooperation Treaty
    Patent Cooperation Treaty Combined (PCT COMB) PCT/US12/046196
    Filed on 2012-07-11
  • US Patent 9,616,139
    Filed on 2014-09-08

Publications

Collaborations

  • Collaboration

Collaboration Description

  • The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize conjugate vaccines. For collaboration opportunities, please contact Marguerite J. Miller, M.B.A. at 301-496-9003 or millermarg@niddk.nih.gov.
Date Published